KV Pharmaceutical Reaches Agreement with U.S. Department of Justice
February 25, 2010 - St. Louis, MO—February 25, 2010 — KV Pharmaceutical Company (NYSE: KVa/KVb) (“the Company”) today announced that it has reached an agreement, subject to court approval, with the United States Attorney for the Eastern District of Missouri and the Office of Consumer Litigation of the United States Department of Justice to resolve an investigation regarding certain activities of ETHEX Corporation, its generic pharmaceutical marketing and distribution subsidiary, which occurred in 2008. Under the terms of the settlement, ETHEX will plead guilty to criminal charges, and will be required to pay a fine and restitution of $25.8 million. ETHEX also will not contest an administrative forfeiture of $1.8 million.

KV Pharmaceutical Amends Agreement to Secure Rights to Gestiva™
January 11, 2010 - St. Louis, MO—January 11, 2010—KV Pharmaceutical Company (NYSE: KVa/KVb) today announced it has entered into an amendment to the existing asset purchase agreement with Hologic, Inc. to secure the full U.S. and worldwide rights to Gestiva?, subject to the terms and conditions set forth in the amendment. Upon approval by the U.S. Food and Drug Administration (the “FDA”), Gestiva? will be the first and only FDA-approved treatment for the prevention of preterm birth in women who are pregnant with a single baby and have spontaneously delivered a single baby preterm in the past. A description of certain material terms and conditions of the amendment to the existing asset purchase agreement with Hologic, Inc. is set forth in the Current Report on Form 8-K filed by the Company today with the SEC.

KV Pharmaceutical Receives Report From Inspector of Elections Certifying Votes to Approve Appointment of Director
January 7, 2010 - St. Louis, MO — January 7, 2010 — KV Pharmaceutical Company (NYSE: KVa/KVb) today announced that IVS Associates, Inc., the inspector of elections retained by the Company, has certified that the votes represented by a written consent of stockholders received by the Company on December 22, 2009 (the “Written Consent”) relating to the appointment of a director by certain stockholders (the “Director Changes”) are sufficient to approve the matters set forth in the Written Consent.

ETHEX Corporation Initiated Nationwide Voluntary Recall of a Single Lot of Hydromorphone HCl 2 mg Tablets
December 23, 2008

KV Pharmaceutical Voluntarily Suspends All Shipments of its Approved Tablet-form Drugs
December 23, 2008

For additional press releases, go to the press release archive.